Do analysts recommend CALT or FENC?

Adherex Technologies has a consensus price target of $17.00, indicating a potential upside of 70.34%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Adherex Technologies is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Adherex Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Adherex Technologies (FENC) Competitors

$9.98 -0.37 (-3.57%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$9.99 +0.01 (+0.10%)

As of 10/16/2026 07:30 PM Eastern

Compare

FENC vs. GHRS, CRON, CALT, HROW, and AVLN

Should you buy Adherex Technologies stock or one of its competitors? Adherex Technologies's main competitors and comparable companies include GH Research (GHRS), Cronos Group (CRON), Calliditas Therapeutics AB (publ) (CALT), Harrow (HROW), and Avalyn Pharma (AVLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Adherex Technologies compare to GH Research?

GH Research (NASDAQ:GHRS) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

In the previous week, Adherex Technologies' average media sentiment score of 1.82 beat GH Research's score of 0.91 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
GH Research	Positive
Adherex Technologies	Very Positive

GH Research has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -5.71% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Adherex Technologies	-6.09%	-5.71%	-2.37%

GH Research currently has a consensus target price of $45.00, indicating a potential upside of 147.93%. Adherex Technologies has a consensus target price of $17.00, indicating a potential upside of 70.34%. Given GH Research's stronger consensus rating and higher possible upside, analysts plainly believe GH Research is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Adherex Technologies has higher revenue and earnings than GH Research. Adherex Technologies is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Adherex Technologies	$44.64M	7.86	-$9.74M	-$0.13	N/A

GH Research has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

56.9% of GH Research shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

GH Research beats Adherex Technologies on 8 of the 14 factors compared between the two stocks.

How does Adherex Technologies compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Cronos Group has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	8.07	-$9.45M	$0.20	16.05
Adherex Technologies	$44.64M	7.86	-$9.74M	-$0.13	N/A

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cronos Group presently has a consensus price target of $2.30, indicating a potential downside of 28.35%. Adherex Technologies has a consensus price target of $17.00, indicating a potential upside of 70.34%. Given Adherex Technologies' higher probable upside, analysts clearly believe Adherex Technologies is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cronos Group has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

In the previous week, Cronos Group had 7 more articles in the media than Adherex Technologies. MarketBeat recorded 7 mentions for Cronos Group and 0 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 1.82 beat Cronos Group's score of 0.90 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Cronos Group	Positive
Adherex Technologies	Very Positive

Cronos Group has a net margin of 39.08% compared to Adherex Technologies' net margin of -6.09%. Cronos Group's return on equity of 4.85% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Adherex Technologies	-6.09%	-5.71%	-2.37%

Summary

Cronos Group beats Adherex Technologies on 10 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

In the previous week, Adherex Technologies' average media sentiment score of 1.82 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Adherex Technologies	Very Positive

Adherex Technologies has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Adherex Technologies is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Adherex Technologies	$44.64M	7.86	-$9.74M	-$0.13	N/A

Adherex Technologies has a consensus price target of $17.00, indicating a potential upside of 70.34%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Adherex Technologies is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Adherex Technologies has a net margin of -6.09% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Adherex Technologies' return on equity of -5.71% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Adherex Technologies	-6.09%	-5.71%	-2.37%

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Adherex Technologies beats Calliditas Therapeutics AB (publ) on 12 of the 15 factors compared between the two stocks.

How does Adherex Technologies compare to Harrow?

Harrow (NASDAQ:HROW) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Harrow has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Harrow has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Harrow, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	3.76	-$5.14M	-$1.00	N/A
Adherex Technologies	$44.64M	7.86	-$9.74M	-$0.13	N/A

In the previous week, Harrow had 3 more articles in the media than Adherex Technologies. MarketBeat recorded 3 mentions for Harrow and 0 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 1.82 beat Harrow's score of 0.06 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Harrow	Neutral
Adherex Technologies	Very Positive

72.8% of Harrow shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Adherex Technologies has a net margin of -6.09% compared to Harrow's net margin of -13.51%. Adherex Technologies' return on equity of -5.71% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Adherex Technologies	-6.09%	-5.71%	-2.37%

Harrow presently has a consensus target price of $66.17, indicating a potential upside of 142.55%. Adherex Technologies has a consensus target price of $17.00, indicating a potential upside of 70.34%. Given Harrow's stronger consensus rating and higher probable upside, analysts clearly believe Harrow is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Harrow beats Adherex Technologies on 9 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to Avalyn Pharma?

Adherex Technologies (NASDAQ:FENC) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Avalyn Pharma has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Avalyn Pharma's return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-6.09%	-5.71%	-2.37%
Avalyn Pharma	N/A	N/A	N/A

55.5% of Adherex Technologies shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Adherex Technologies currently has a consensus price target of $17.00, indicating a potential upside of 70.34%. Avalyn Pharma has a consensus price target of $60.00, indicating a potential upside of 153.59%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Avalyn Pharma is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Avalyn Pharma has lower revenue, but higher earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	7.86	-$9.74M	-$0.13	N/A
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

In the previous week, Avalyn Pharma had 2 more articles in the media than Adherex Technologies. MarketBeat recorded 2 mentions for Avalyn Pharma and 0 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 1.82 beat Avalyn Pharma's score of 0.06 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adherex Technologies	Very Positive
Avalyn Pharma	Neutral

Summary

Avalyn Pharma beats Adherex Technologies on 8 of the 14 factors compared between the two stocks.

Get Adherex Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FENC vs. The Competition

Export

Metric	Adherex Technologies	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$363.68M	$12.72B	$7.47B	$12.95B
Dividend Yield	N/A	2.61%	2.50%	27.63%
P/E Ratio	-76.77	802.67	273.86	24.84
Price / Sales	7.86	750.13	571.54	76.69
Price / Cash	N/A	81.56	76.54	51.88
Price / Book	9.60	9.21	10.31	5.85
Net Income	-$9.74M	$2.85B	$3.51B	$381.63M
7 Day Performance	-6.82%	-5.24%	-5.46%	-5.04%
1 Month Performance	-7.42%	-9.17%	-9.65%	-7.99%
1 Year Performance	21.12%	-6.06%	0.74%	-5.68%

Adherex Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FENC Adherex Technologies	4.5 of 5 stars	$9.98 -3.6%	$17.00 +70.3%	+15.5%	$363.68M	$44.64M	N/A	35	Positive News Analyst Forecast
GHRS GH Research	3.6075 of 5 stars	$20.45 -2.9%	$45.00 +120.0%	+31.3%	$1.44B	N/A	N/A	73	Analyst Forecast
CRON Cronos Group	1.807 of 5 stars	$3.22 -0.6%	$2.30 -28.6%	+29.4%	$1.19B	$179.09M	16.10	610	News Coverage
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
HROW Harrow	2.1102 of 5 stars	$30.52 -0.3%	$66.17 +116.8%	-28.1%	$1.15B	$275.59M	N/A	373	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FENC) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adherex Technologies (FENC) Competitors

FENC vs. GHRS, CRON, CALT, HROW, and AVLN

How does Adherex Technologies compare to GH Research?

Summary

How does Adherex Technologies compare to Cronos Group?

Summary

How does Adherex Technologies compare to Calliditas Therapeutics AB (publ)?

Summary

How does Adherex Technologies compare to Harrow?

Summary

How does Adherex Technologies compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC vs. The Competition

Adherex Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adherex Technologies (FENC) Competitors

FENC vs. GHRS, CRON, CALT, HROW, and AVLN

How does Adherex Technologies compare to GH Research?

Does the media refer more to GHRS or FENC?

Is GHRS or FENC more profitable?

Do analysts rate GHRS or FENC?

Which has higher earnings & valuation, GHRS or FENC?

Which has more volatility and risk, GHRS or FENC?

Do institutionals & insiders have more ownership in GHRS or FENC?

Summary

How does Adherex Technologies compare to Cronos Group?

Which has preferable valuation & earnings, CRON or FENC?

Do insiders & institutionals have more ownership in CRON or FENC?

Do analysts rate CRON or FENC?

Which has more volatility & risk, CRON or FENC?

Does the media refer more to CRON or FENC?

Is CRON or FENC more profitable?

Summary

How does Adherex Technologies compare to Calliditas Therapeutics AB (publ)?

Which has more volatility and risk, CALT or FENC?

Does the media favor CALT or FENC?

Which has stronger valuation and earnings, CALT or FENC?

Do analysts recommend CALT or FENC?

Is CALT or FENC more profitable?

Do insiders & institutionals believe in CALT or FENC?

Summary

How does Adherex Technologies compare to Harrow?

Which has more risk & volatility, HROW or FENC?

Which has better valuation & earnings, HROW or FENC?

Does the media favor HROW or FENC?

Do insiders and institutionals believe in HROW or FENC?

Is HROW or FENC more profitable?

Do analysts recommend HROW or FENC?

Summary

How does Adherex Technologies compare to Avalyn Pharma?

Is FENC or AVLN more profitable?

Do insiders and institutionals believe in FENC or AVLN?

Do analysts prefer FENC or AVLN?

Which has higher valuation & earnings, FENC or AVLN?

Does the media refer more to FENC or AVLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC vs. The Competition

Adherex Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools